论文部分内容阅读
目的 :观察重组人干扰素-γ(IFN-γ)联合激素治疗特发性肺间质纤维化(Idiopathic pulmonary fibrosis,IPF)患者的疗效。方法 :临床纳入IPF患者100例,根据患者入院后治疗方案的不同分为研究组与对照组,研究组给予IFN-γ联合激素治疗,对照组仅给予激素治疗。观察治疗前后两组患者Ⅲ型胶原(Collagen TypeⅢ,Ⅲ-C)、IV型胶原(Collagen Type IV,IV-C)、透明质酸(Hyaluronic acid,HA)水平;此外,观察两组患者治疗前后临床症状、胸部CT、肺弥散功能等指标的变化。结果 :治疗前,两组患者Ⅲ-C、IV-C、HA水平差异均未见显著性;治疗后,研究组Ⅲ-C、IV-C、HA水平分别为(49.57±4.31)ng/m L、(64.39±17.98)ng/m L、(79.01±22.84)ng/m L,对照组Ⅲ-C、IV-C、HA水平分别为(80.36±5.09)ng/m L、(73.33±18.94)ng/m L、(90.944±21.67)ng/m L,差异均有显著性;研究组患者呼吸困难、刺激性干咳、活动能力以及肺弥散功能好转率分别为52.0%、56.0%、60.0%、64.0%,对照组分别为24.0%、24.0%、28.0%、32.0%,差异均有显著性。结论 :IFN-γ联合激素治疗IPF,能够有效改善患者呼吸困难、刺激性干咳等临床症状,改善其活动能力以及肺弥散功能,且能够有效改善肺纤维化的程度,值得推广。
Objective: To observe the effect of recombinant interferon-γ (IFN-γ) combined with hormone therapy in patients with idiopathic pulmonary fibrosis (IPF). Methods: One hundred patients with IPF were enrolled in this study. The patients were divided into study group and control group according to different treatment regimens after admission. The study group received IFN-γ combined with hormone therapy while the control group only received hormone therapy. The levels of Collagen Type Ⅲ, Ⅲ-C, IV-C and Hyaluronic acid (HA) in both groups were observed before and after treatment. In addition, Clinical symptoms, chest CT, pulmonary diffuse function and other indicators of change. Results: Before treatment, the levels of Ⅲ-C, IV-C and HA were not significantly different between the two groups. After treatment, the levels of Ⅲ-C, IV-C and HA in the study group were (49.57 ± 4.31) ng / m (64.39 ± 17.98) ng / m L and (79.01 ± 22.84) ng / m L, respectively. The levels of Ⅲ-C and IV-C and HA in the control group were (80.36 ± 5.09) ng / m L and (73.33 ± 18.94 (90.944 ± 21.67) ng / m L, the difference was significant. The improvement rates of dyspnea, irritating dry cough, activity and pulmonary diffusing capacity in study group were 52.0%, 56.0% and 60.0% , 64.0% in the control group and 24.0%, 24.0%, 28.0% and 32.0% in the control group respectively. The difference was significant. Conclusion: IFN-γ combined with hormone treatment of IPF can effectively improve clinical symptoms such as dyspnea and irritating cough, improve its activity and lung diffusion function, and can effectively improve the degree of pulmonary fibrosis. It is worth popularizing.